The real-world efficacy and safety of frontline therapy of obinutuzumab plus bendamustine for untreated high-tumor-burden follicular lymphoma.
Nagata H, Tsukamoto T, Kobayashi T, Takahashi R, Okano A, Uchiyama H, Kawata E, Uoshima N, Kaneko H, Fuchida SI, Nishiyama D, Nakao M, Fujino T, Mizutani S, Shimura Y, Kuroda J.
Nagata H, et al. Among authors: kuroda j.
Int J Clin Oncol. 2025 Jan 7. doi: 10.1007/s10147-025-02691-8. Online ahead of print.
Int J Clin Oncol. 2025.
PMID: 39776016